06/20/22 4:00 PMNasdaq : PTCT conferencesPTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular DystrophyPTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The callRHEA-AIneutral
06/09/22 8:00 AMNasdaq : PTCT managementBiotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of DirectorsPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing. She is currently theRHEA-AIneutral
06/06/22 8:00 AMNasdaq : PTCT conferencesPTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock ConferencePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ETThe presentation will be webcast live on theRHEA-AIneutral
06/03/22 8:00 AMNasdaq : PTCT Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma StudyPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1BRHEA-AIneutral
05/31/22 1:00 AMNasdaq : PTCT fda approvalFDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months OldPTC Therapeutics, Inc. (NASDAQ: PTCT)RHEA-AIneutral
05/20/22 8:08 AMNasdaq : PTCT PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency– First ever gene therapy directly administered into the brain –– Recommended for regulatory approval by EMA –– Results demonstrated sustained improvements in motor and cognitive function –– Conference call scheduled for Monday, May 23, at 8 a.m. ET –SOUTH PLAINFIELD, N.J. , May 20, 2022RHEA-AIpositive
05/03/22 4:01 PMNasdaq : PTCT earningsPTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial ResultsRHEA-AIneutral
04/29/22 4:30 PMNasdaq : PTCT conferencesPTC Therapeutics to Participate at Upcoming Investor ConferencesPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m. PT2022 RBC Capital MarketsRHEA-AIneutral
04/19/22 8:00 AMNasdaq : PTCT conferencesearningsPTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial ResultsPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3, atRHEA-AIneutral
04/14/22 8:30 AMNasdaq : PTCT PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy ProgramPTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) withRHEA-AIneutral